Gb Sciences identifies new cannabis-inspired blends that could treat viral infections

GB Sciences, Inc. (OTCQB: GBLX), a leading plant-inspired biopharmaceutical R&D development company, recently published a study that demonstrates the potential of certain cannabinoids and terpenes to reduce blood sugar. 'inflammation. She is currently developing cannabinoid-based anti-inflammatory therapies to help fight viral infections in the future.

A recently released white paper on its new development program, "Utilizing Proprietary AI/ML Technology, Novel Cannabis-Inspired Mixtures Are Developed as Innovative Anti-Inflammatory Therapeutics," notes that formulations of Gb Sciences are being developed to treat Cytokine Release Syndrome (CRS) caused by viral infections like COVID-19 and others.

During the pandemic, "6.3 million people died from hyperinflammatory side effects linked to this viral infection, which inspired Gb Sciences to create anti-inflammatory drugs designed to treat future viral epidemics that cause these dangerous hyperinflammatory diseases". responses,” according to a press release.

Andrea Small-Howard, President and Chief Scientific Officer of Gb Sciences, said their "cannabis-inspired therapy was designed to reset the immune system after the onset of hyperinflammation, providing a relief by targeting our human immune system response to a virus, without being tied to a specific variant or the virus itself.”

Cannabis-Inspired Anti-Inflammatory Therapies

Gb Sciences' CRS therapy stands out for its potential for early intervention and prevention for patients who discover for the first time that they have been exposed to a virus that causes hyperinflammation .

"This therapy may also be useful for patients who suffer from CRS as a side effect of certain new cancer treatments, such as bispecific single-chain antibody constructs engaging T cells (BiTE) and chimeric antigen receptor T cells (CAR),” according to the press release.

In early May, the company announced that FHI Clinical would consult and write the draft clinical trial protocol for the first-in-human trial of these proprietary cannabinoid-containing formulations. Additionally, "a proof-of-concept study by Michigan State University researchers assessed the potential of Gb Sciences' cannabis-derived blends to suppress immunological responses that contribute to virus symptoms," according to its new development program. .

According to Precedence Research, the global anti-inflammatory therapy market size was estimated at $99.6 billion in 2021 and is expected to reach $127.5 billion by 2030, with a recorded CAGR of 4.5% from 2022 to 2030.

Get your daily dose ofcannabis news on Benzinga Cannabis. Don't miss any important developments in the industry.

Photo: courtesy of CDC on Unsplash

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.